GlassScriptPhysician profile
Arvind G Kamthan
NPI 1073507653
$1,372.18
in general payments reported to CMS, 2019-2025
21 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.06 · 2020: $89.67 · 2021: $228 · 2022: $139 · 2023: $331 · 2024: $242 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.57 | 2020-2025 | Tagrisso, Imfinzi |
| Amgen INC. | $233.03 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $120.59 | 2021-2024 | Krazati, Augtyro, Opdivo |
| Incyte Corporation | $99.95 | 2021 | |
| Merck Sharp & Dohme LLC | $81.74 | 2019-2025 | Keytruda, Lynparza |
| Accord Healthcare, INC. | $55.59 | 2025 | |
| Astellas Pharma US INC | $52.36 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $46.97 | 2024 | |
| Alnylam Pharmaceuticals INC. | $37.62 | 2025 | Onpattro |
| Rigel Pharmaceuticals, INC. | $31.25 | 2020 | |
| Celgene Corporation | $28.59 | 2023 | Opdualag |
| Coherus Oncology, INC. | $21.64 | 2024 | |
| Taiho Oncology, INC. | $21.47 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.69 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.00 | 2019 | |
| Tempus Ai, INC | $19.12 | 2025 | Xt Cdx |
| Csl Behring | $17.92 | 2023 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2019 | |
| Genentech USA, INC. | $16.63 | 2025 | Itovebi |
| Glaxosmithkline, LLC. | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Kamthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.